PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease

NCT01581073 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

476

Enrollment

OTHER

Sponsor class

Conditions

Chronic Kidney Disease
Diabetes

Interventions

DRUG: Darbepoetin alfa

Sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Collaborators

[object Object]